Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633550 | 0.93 | — | — | |
| SCHEMBL199063 | 0.93 | — | — | |
| SCHEMBL199062 | 0.93 | — | — | |
| SCHEMBL27685893 | 0.91 | ACE (0.46) | ACELMNACYP2C19HSD17B10 | |
| SCHEMBL27685894 | 0.91 | ACE (0.46) | ACELMNACYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL27857098 | 0.91 | ACE (0.46) | ACELMNACYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL28366660 | 0.91 | ACE (0.46) | ACELMNACYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL28366662 | 0.91 | ACE (0.46) | ACELMNACYP2C19HSD17B10 | |
| SCHEMBL4951219 | 0.83 | — | — | |
| SCHEMBL29951832 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004000806-A1 | AMIDES OF CYCLIC AMINO ACIDS USED AS PDE 4 INHIBITORS | ELBION AG (DE) | 2003-12-31 | — | — | WO | claimed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| CN-109400607-A | AVM hereinafter Batan intermediate and preparation method thereof | 江苏奥赛康药业股份有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-2386539-B1 | 4-Aminoproline derivatives useful as lysine mimetics | ZEALAND PHARMA AS (DK) | 2016-07-20 | — | — | EP | disclosed |
| EP-1966130-B1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA AS (DK) | 2013-12-11 | — | — | EP | disclosed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
| WO-2004000806-A1 | AMIDES OF CYCLIC AMINO ACIDS USED AS PDE 4 INHIBITORS | ELBION AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | ACE 863/4885ALDH1A1 1510/4885MAPT 3437/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | ACE 863/4885ALDH1A1 1510/4885MAPT 3437/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | ACE 863/4885ALDH1A1 1510/4885MAPT 3437/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | ACE 863/4885ALDH1A1 1510/4885MAPT 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.